Affinage

Showing NFATC1 — NFATC is a alias.

NFATC1

Nuclear factor of activated T-cells, cytoplasmic 1 · UniProt O95644

Length
943 aa
Mass
101.2 kDa
Annotated
2026-06-10
100 papers in source corpus 50 papers cited in narrative 50 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

NFATc1 is a Ca2+/calcineurin-regulated transcription factor whose DNA-binding domain adopts a Rel-like fold that recognizes target promoters and cooperates with partner factors such as AP-1 on composite elements (PMID:8990122). Its activity is gated by phosphorylation: GSK-3, JNK, ERK, p38, CK2, and IKKε associate with and phosphorylate conserved Ser-Pro repeat motifs and Ser172 in the N-terminal regulatory domain, opposing calcineurin-mediated dephosphorylation by promoting cytoplasmic retention/nuclear export and reducing intrinsic DNA binding, while calcineurin dephosphorylation drives nuclear import and enhances DNA binding (PMID:9072970, PMID:11063740, PMID:10652349, PMID:27346349). Protein abundance is further tuned by phosphorylation-dependent stabilization through Cot/Tpl-2 and DYRK1A (which block ubiquitination) and by SUMOylation that represses IL-2 output (PMID:28235034, PMID:32986812, PMID:22615493). The best-defined biological role of NFATc1 is as the master transcriptional switch for terminal osteoclast differentiation downstream of RANKL-TRAF6-c-Fos and Ca2+/calcineurin signaling (PMID:12479813); its induction at the Nfatc1 locus depends on STAT3 and on serine-synthesis-derived α-ketoglutarate that feeds histone demethylases to remove repressive marks, and it drives an osteoclastogenic gene program including CCR1, SLC7A11, and miR182 (PMID:31462535, PMID:38200114, PMID:37148740, PMID:16355273, PMID:31908034). Beyond bone, NFATc1 governs lymphocyte development and function—B-1a cell development, pro-B to pre-B transition via EBF1, cytotoxic T cell effector functions and glycolytic reprogramming, follicular regulatory T cell homing via CXCR5, and anergy programs—and it controls cardiac valve, lymphatic, and epicardial development, hair follicle stem cell quiescence through CDK4 repression, and disease-associated transcriptional programs in cancer and metabolic/fibrotic tissues (PMID:18243104, PMID:24590764, PMID:14595020, PMID:19233265, PMID:28894104, PMID:32070236, PMID:28970470, PMID:29907883, PMID:35365570).

Mechanistic history

Synthesis pass · year-by-year structured walk · 22 steps
  1. 1997 High

    Established how NFATc activity is negatively controlled, identifying GSK-3 as a kinase that phosphorylates the conserved N-terminal serines to drive nuclear export and oppose Ca2+-calcineurin import.

    Evidence Biochemical purification of NF-AT kinase and in vitro phosphorylation with nuclear localization assays

    PMID:9072970

    Open questions at the time
    • Did not map all physiological GSK-3 priming events
    • In vivo relevance to specific tissues not addressed
  2. 1997 High

    Defined the structural basis of NFATc DNA recognition, showing a Rel-like DBD necessary and sufficient for binding and cooperative activation distinct from NF-κB p50.

    Evidence NMR solution structure with DNA binding and transcriptional activation assays

    PMID:8990122

    Open questions at the time
    • No structure of full-length protein or partner co-complexes
    • AP-1 cooperativity modeled but not crystallographically resolved
  3. 2000 High

    Extended kinase regulation by showing GSK-3 and MAPKs/CK2 phosphorylation controls not only localization but also intrinsic DNA binding, and that multiple kinases physically dock on the N-terminal domain to block nuclear translocation.

    Evidence EMSA, in vitro kinase assays, Co-IP, mutant analysis, and subcellular localization assays

    PMID:10652349 PMID:11063740

    Open questions at the time
    • Stoichiometry and ordering of multi-kinase phosphorylation unresolved
    • Phosphatase counteraction kinetics not defined
  4. 1999 Medium

    Showed NFATc1 isoform diversity generates distinct transactivation capacities, with isoform C containing a second TAD and isoform B exerting suppression.

    Evidence Alternative splicing analysis, TAD mapping, reporter and phosphorylation assays in T cells

    PMID:10358178

    Open questions at the time
    • Single lab characterization
    • Tissue-specific isoform usage not mapped
  5. 2002 High

    Identified NFATc1 as the master transcriptional switch for terminal osteoclast differentiation downstream of RANKL-TRAF6-c-Fos and Ca2+/calcineurin signaling.

    Evidence NFATc1-deficient ES cell differentiation, ectopic expression, Ca2+ imaging, pathway genetics

    PMID:12479813

    Open questions at the time
    • Full downstream target program not enumerated at the time
    • Mechanism of sustained autoamplification not detailed
  6. 2002 Medium

    Clarified that disparate NFATc1 vs NFATc2 cytokine phenotypes arise from differential regulation rather than intrinsic transcriptional differences at IL-4.

    Evidence Constitutively active alanine-substitution mutants with IL-4 transcription assays in T cells

    PMID:12355451

    Open questions at the time
    • Single transcriptional readout
    • Differential upstream regulation not directly dissected
  7. 2002 Medium

    Demonstrated NFATc1 cooperates with GATA5 to drive endocardial differentiation, linking it to early cardiac development.

    Evidence In vitro cardiogenic differentiation with loss-of-function and synergy reporter assays

    PMID:12163407

    Open questions at the time
    • In vitro model only
    • Direct target genes not identified
  8. 2008 High

    Revealed a repressive transcriptional role in stem cell maintenance, with NFATc1 repressing CDK4 to keep hair follicle stem cells quiescent downstream of BMP.

    Evidence Conditional and complete gene ablation, calcineurin inhibition, reporter/ChIP for CDK4

    PMID:18243104

    Open questions at the time
    • Co-repressor machinery at CDK4 not defined
    • Generalizability to other stem cell niches untested
  9. 2003 High

    Established a cell-intrinsic, NFATc1-specific (vs NFATc2) requirement for B-1a cell development.

    Evidence NFATc1- and NFATc2-deficient mice, mixed chimeras, retroviral rescue, flow cytometry

    PMID:14595020

    Open questions at the time
    • Direct B-1a target genes not identified
    • Isoform responsible not resolved
  10. 2009 High

    Defined cross-regulation among NFAT family members and FOXP3, showing FOXP3 competes with NFAT1 at the NFATc1 promoter to enforce Treg anergy, and IL-2/IL-15 differentially recruit NFAT2 vs NFAT1 to target promoters.

    Evidence ChIP, inducible FOXP3 expression, retroviral rescue, promoter mutation, NFAT1-/- mice

    PMID:15347678 PMID:19564342

    Open questions at the time
    • Determinants of family-member-selective recruitment unresolved
    • In vivo competition dynamics not quantified
  11. 2011 High

    Extended NFATc1 to developmental ECM remodeling, showing RANKL/calcineurin-NFATC1 induces cathepsin K to enable epicardium-derived cell invasion.

    Evidence Conditional EPDC knockout, RANKL treatment, in vivo CTSK analysis, calcineurin inhibition

    PMID:21447555

    Open questions at the time
    • Direct CTSK promoter occupancy not shown
    • Other invasion effectors not enumerated
  12. 2009 High

    Established a requirement for NFATc1 in lymphatic endothelial coalescence and lymphatic gene expression.

    Evidence Knockout mice, in utero cyclosporin A, siRNA, reporter assays, immunofluorescence

    PMID:19233265

    Open questions at the time
    • Direct vs indirect regulation of VEGFR-3/podoplanin not separated
    • Upstream activator in lymphatics unclear
  13. 2013 High

    Connected calcineurin-NFATc1 signaling to disease-driving transcriptional programs across multiple tissues including cardiac hypertrophy feedback (Itpr2), chondroprotection, podocyte apoptosis (Bax), and cancer invasion.

    Evidence ChIP/promoter assays, transgenic and conditional KO mice, inducible constitutively active NFATc1, invasion and apoptosis assays

    PMID:23340267 PMID:23811942 PMID:24248346 PMID:24415751

    Open questions at the time
    • Context-specific cofactors driving opposite (activating vs repressive) outputs unresolved
    • Several cancer findings are single-lab Medium-confidence
  14. 2014 High

    Mapped upstream transcriptional induction of NFATc1 itself in B cells (NF-κB1/p50 and c-Rel at the P1 promoter) and defined its role in early B cell development via EBF1 and immunoglobulin rearrangement.

    Evidence B cell-specific NF-κB and NFATc1 knockouts, promoter-reporter binding-site analysis, Ig rearrangement assays

    PMID:25179582 PMID:29907883

    Open questions at the time
    • Direct EBF1 promoter occupancy by NFATc1 not shown
    • Isoform-specific contributions not separated
  15. 2014 High

    Defined NFATc1 control of follicular regulatory T cell positioning via CXCR5 upregulation, with autoimmune consequences.

    Evidence T cell-specific Nfat2 conditional knockout, immunization, flow cytometry, disease scoring

    PMID:24590764

    Open questions at the time
    • Direct Cxcr5 promoter binding not demonstrated
    • Cofactor requirements in TFR cells unknown
  16. 2016 Medium

    Identified IKKε as an additional negative regulatory kinase retaining NFATc1 in the cytoplasm to dampen T cell antitumor/antiviral immunity.

    Evidence Kinase assay, T cell activation assays, IKKε knockout mice, tumor/viral models

    PMID:27346349

    Open questions at the time
    • Phosphosite mapping incomplete
    • Single lab
  17. 2017 High

    Showed NFATc1 directly programs cytotoxic T cell effector function, synapse organization, and glycolytic metabolic switching, with genome-wide target identification including Tbx21 and Gzmb.

    Evidence Conditional T cell KO, ChIP-seq, transcriptomics, metabolic assays, in vivo models

    PMID:28894104

    Open questions at the time
    • Direct vs indirect metabolic gene targets not fully separated
    • IL-2 rescue mechanism not fully resolved
  18. 2017 Medium

    Resolved a paradoxical positive post-translational regulation: DYRK1A phosphorylation at specific serines blocks NFATc1 ubiquitination and stabilizes it, opposite to its effect on NFATc2.

    Evidence In vitro kinase assay with site mutagenesis, ubiquitination assay, stability and reporter assays

    PMID:28235034

    Open questions at the time
    • E3 ligase blocked by phosphorylation not identified
    • In vivo relevance limited
  19. 2019 High

    Established STAT3 as a direct transcriptional activator of the Nfatc1 gene in osteoclast precursors, placing NFATc1 induction within a defined upstream cascade.

    Evidence Osteoclast-specific Stat3 conditional KO, ChIP, NFATc1 rescue, STAT3 inhibitor

    PMID:31462535

    Open questions at the time
    • Interplay with calcineurin-driven autoamplification not dissected
    • Other STAT3 cofactors at the locus unknown
  20. 2021 High

    Demonstrated SUMOylation as a physiological brake on NFATc1, repressing IL-2 to limit Treg expansion and autoimmunity in vivo.

    Evidence SUMO-site mutant transgenic mice, EAE and GVHD models, cytokine/TF analysis

    PMID:32986812

    Open questions at the time
    • SUMO E3 ligase and target lysines mechanistic detail limited
    • Tissue-specificity of SUMO regulation not mapped
  21. 2023 Medium

    Uncovered additional layers of stability control and metabolic gene coupling, including UCHL1-TAZ competition with calcineurin for NFATc1 and NFATc1-driven SLC7A11 import linking osteoclast precursors to disulfidptosis.

    Evidence Conditional KOs, Co-IP competition, ubiquitination biochemistry, ChIP, pharmacological rescue, OVX models

    PMID:37148740 PMID:37215988

    Open questions at the time
    • Single-lab findings
    • Direct structural basis of TAZ-calcineurin competition for NFATc1 not resolved
  22. 2024 High

    Linked metabolism to NFATc1 induction epigenetically, showing serine-synthesis-derived α-ketoglutarate is required for histone demethylation at the Nfatc1 locus during osteoclastogenesis.

    Evidence Osteoclast progenitor PHGDH deletion, histone methylation analysis, metabolite rescue, OVX model

    PMID:38200114

    Open questions at the time
    • Specific demethylases acting at the locus not definitively assigned
    • Generalizability beyond osteoclasts untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How tissue- and context-specific cofactors switch NFATc1 between transcriptional activation and repression of overlapping target sets, and how the full network of stabilizing vs destabilizing post-translational modifications is integrated in vivo, remains unresolved.
  • No unified model of activator-vs-repressor output selection
  • E3 ligases and SUMO machinery acting on NFATc1 incompletely defined
  • Isoform-specific functional division of labor not comprehensively mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 4
Localization
GO:0005634 nucleus 4 GO:0005829 cytosol 3
Pathway
R-HSA-168256 Immune System 5 R-HSA-1266738 Developmental Biology 4 R-HSA-162582 Signal Transduction 4 R-HSA-74160 Gene expression (Transcription) 4 R-HSA-1430728 Metabolism 3
Partners
DYRK1AFOXP3GSK3BHOMER2HOMER3PPP3CASOX2TAZ

Evidence

Reading pass · 50 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2002 RANKL selectively induces NFATc1 expression via TRAF6 and c-Fos signaling pathways, evokes Ca2+ oscillations leading to calcineurin-mediated NFATc1 activation, and triggers a sustained NFATc1-dependent transcriptional program during osteoclast differentiation. NFATc1-deficient embryonic stem cells fail to differentiate into osteoclasts in response to RANKL, and ectopic NFATc1 expression causes precursor cells to differentiate without RANKL, establishing NFATc1 as a master transcriptional switch downstream of RANKL for terminal osteoclast differentiation. NFATc1-deficient ES cell differentiation assay, ectopic NFATc1 expression, Ca2+ oscillation imaging, genetic epistasis (TRAF6/c-Fos pathways) Developmental cell High 12479813
1997 Glycogen synthase kinase-3 (GSK-3) is a component of the NF-ATc kinase that phosphorylates conserved serines in the NF-ATc N-terminus, promotes nuclear export, and thereby opposes Ca2+-calcineurin signaling that drives nuclear import. Biochemical purification of NF-AT kinase, in vitro phosphorylation assay, nuclear localization assays Science High 9072970
2000 GSK-3 phosphorylation of the conserved Ser-Pro repeat motifs in NFATc negatively regulates its intrinsic DNA binding activity, in addition to controlling its subcellular localization; calcineurin-mediated dephosphorylation enhances DNA binding. Gel mobility shift assay, in vitro phosphorylation, NFATc mutant analysis The Journal of biological chemistry High 11063740
2000 JNK, ERK, p38, and CK2 physically associate with the NFATc N-terminal regulatory domain and directly phosphorylate Ser172 and conserved Ser-Pro repeats, blocking ionomycin-induced nuclear translocation; CK2 additionally phosphorylates a conserved motif downstream of the Ser-Pro repeats important for nuclear export. Co-immunoprecipitation, in vitro kinase assay, overexpression/inhibitor studies, subcellular localization assay The Journal of biological chemistry High 10652349
1997 The DNA-binding domain (DBD) of NFATc has an unusual Rel-like fold that is both necessary and sufficient for DNA binding and cooperative transcriptional activation; despite overall structural homology to NF-κB p50, the two proteins use significantly different strategies for DNA recognition. A model was proposed for cooperative complex formation with AP-1 on the IL-2 enhancer. NMR solution structure determination, DNA binding assays, transcriptional activation assays Nature High 8990122
2001 NFATc1 (NFATc) undergoes activity-dependent nuclear translocation in adult skeletal muscle fibers: slow-twitch electrical stimulation patterns (10 Hz continuous or 5-s trains) drive cyclosporin A-sensitive nuclear accumulation of NFATc-GFP foci, whereas fast-twitch patterns (50 Hz) or low-frequency (1 Hz) stimulation do not, indicating NFATc1 nuclear import contributes to slow fiber-type gene regulation. Live-cell GFP imaging in adult muscle fibers, electrical stimulation, pharmacological inhibition (cyclosporin A), kinase inhibitors The Journal of cell biology High 11581284
2008 NFATc1 is preferentially expressed by hair follicle stem cells in their niche downstream of BMP signaling, where it transcriptionally represses CDK4 to maintain stem cell quiescence; pharmacological or genetic ablation of calcineurin/NFATc1 signaling causes premature stem cell activation and precocious follicular growth. Conditional and complete NFATc1 gene ablation, pharmacological calcineurin inhibition, reporter/ChIP assays for CDK4 repression Cell High 18243104
2008 NFATc1 binds a novel regulatory element at the pdcd1 (PD-1) locus and is required for PD-1 gene transcription upon T cell stimulation; mutation of the NFATc1 binding site abolishes promoter activity. Chromatin immunoprecipitation, reporter gene assay with binding site mutagenesis, calcineurin inhibitor and NFAT-specific inhibitor treatment Journal of immunology High 18802087
1999 NFATc1 isoforms B and C contain long C-terminal extensions beyond the previously described isoform A; isoform C possesses a second transactivation domain (TAD-B) in its C-terminal peptide that responds to T cell stimuli similarly to TAD-A but remains unphosphorylated, while isoform B exerts suppressive transcriptional effects through its shorter C-terminal peptide. Alternative splicing analysis, transactivation domain mapping, reporter assays, phosphorylation analysis in stimulated T cells Journal of immunology Medium 10358178
2002 NFATc1 and NFATc2 are both positive regulators of IL-4 gene transcription with intrinsically similar DNA-binding and transcriptional activities at the IL-4 gene, suggesting that the disparate IL-4 phenotypes in NFAT1−/− vs. NFAT2−/− T cells arise from differential regulation of the two proteins rather than intrinsic differences in their transcriptional activities. Constitutively active NFATc mutants (alanine substitutions), IL-4 transcription assays in T cells European journal of immunology Medium 12355451
2014 NFAT2 (NFATc1) is required in follicular regulatory T cells (TFR) to upregulate CXCR5 expression, enabling their homing to B cell follicles; T cell-specific NFAT2 ablation reduces TFR cells in follicular populations and exacerbates lupus-like autoimmune disease. T cell-specific Nfat2 conditional knockout mice, immunization experiments, flow cytometry, disease scoring The Journal of experimental medicine High 24590764
2003 NFATc1 is required cell-intrinsically for normal B-1a cell development; NFATc1-deficient mice lack peritoneal and splenic B-1a cells, while NFATc2-deficient mice have a normal B-1a compartment; NFATc1 protein is elevated ~5-fold in B-1a versus B-2 cells. NFATc1-deficient and NFATc2-deficient mouse analysis, mixed-allotype chimeras, retroviral gene transduction, flow cytometry Proceedings of the National Academy of Sciences High 14595020
2006 The calcineurin-NFATc pathway directly regulates AQP2 (aquaporin-2) expression in renal collecting duct cells through functional NFAT binding sites in the AQP2 proximal promoter; hypertonicity promotes nuclear translocation of NFATc proteins (in addition to TonEBP/NFAT5) to induce AQP2, and calcineurin activity is involved in TonEBP/NFAT5 induction by hypertonicity. Promoter mutational analysis, chromatin immunoprecipitation, nuclear translocation assays, calcineurin inhibitor studies American journal of physiology. Cell physiology High 17166937
2011 NFATC1 is expressed in epicardium-derived cells and is required for their invasion into myocardium; RANKL/calcineurin signaling activates NFATC1 to induce cathepsin K (CTSK) expression, enabling ECM degradation and cell invasion; loss of NFATC1 in EPDCs causes reduced coronary vessel and fibrous matrix penetration and embryonic lethality by E18.5. Conditional NFATC1 knockout in EPDCs, RANKL treatment of PE-derived cell cultures, in vivo CTSK expression analysis, calcineurin inhibitor experiments Development High 21447555
2009 NFATc1 is required for lymphatic endothelial development; in NFATc1-null mice, lymphatic endothelial cells fail to properly coalesce into lymph sacs; calcineurin inhibition with cyclosporin A reduces podoplanin and FGFR-3 expression in lymphatics; NFATc1 siRNA reduces VEGFR-3 and podoplanin expression and NFATc1 activates lymphatic-specific gene promoters. NFATc1 knockout mouse analysis, cyclosporin A treatment in utero, siRNA knockdown, reporter assays, immunofluorescence co-localization Mechanisms of development High 19233265
2013 Cartilage-specific ablation of NFATc1 in NFATc2-deficient mice leads to early onset aggressive osteoarthritis with loss of proteoglycans, collagen/aggrecan degradation, osteophyte formation, and joint instability, indicating NFATc1 and NFATc2 cooperate to repress spontaneous OA in chondrocytes. Cartilage-specific NFATc1 conditional knockout in NFATc2-/- mice, histomorphometry, micro-CT, analysis of human OA cartilage samples Proceedings of the National Academy of Sciences High 24248346
2016 IKKε phosphorylates NFATc1 during T cell activation, promoting its cytoplasmic retention and inhibiting T cell antitumor and antiviral immune responses; loss of IKKε elevates T cell immunity, while constitutively nuclear NFATc1 restores sorafenib resistance in IKKε-activated contexts. Kinase assay, T cell activation assays, IKKε knockout mice, tumor and viral infection models Cell reports Medium 27346349
2017 NFATc1 controls cytotoxic T lymphocyte effector functions including cytoskeleton organization, recruitment of cytosolic organelles to immunological synapses, and glycolytic metabolic switching; NFATc1-deficient CD8+ T cells show impaired cytotoxicity and glycolysis that can be restored by IL-2. Genome-wide ChIP-seq confirms NFATc1 binding to genes controlling CTL activity including Tbx21 and Gzmb. Nfatc1 conditional KO in T cells, genome-wide ChIP-seq, transcriptome analysis, metabolic assays, in vivo infection/tumor models Nature communications High 28894104
2017 DYRK1A phosphorylates NFATc1/αA at S261, S278, S403, and S409, which interferes with NFATc1 ubiquitination and proteasomal degradation, thereby stabilizing the protein and increasing its transcriptional activity—contrary to its suppressive role on NFATc2. In vitro kinase assay with site-specific mutagenesis, ubiquitination assay, protein stability assay, transcriptional reporter assay PloS one Medium 28235034
2021 SUMOylation of NFATc1 represses IL-2 production in T cells in vivo; transgenic mice in which NFATc1 SUMOylation is prevented show elevated IL-2, expanded regulatory T cells, and ameliorated autoimmune encephalomyelitis and graft-versus-host disease. Mechanistically, increased IL-2 counteracts IL-17/IFN-γ through STAT5 and Blimp-1 induction. SUMO-site mutant transgenic mouse generation, in vivo EAE and GVHD models, cytokine and transcription factor analysis The Journal of experimental medicine High 32986812
2019 STAT3 drives NFATc1 transcription by directly binding to the NFATc1 promoter in osteoclast precursors; conditional deletion of Stat3 in osteoclasts reduces NFATc1 expression and impairs osteoclast differentiation, and enforced NFATc1 expression rescues the Stat3-deficient differentiation defect. Osteoclast-specific Stat3 conditional knockout (Ctsk-Cre), promoter binding by ChIP, NFATc1 rescue experiments, STAT3 inhibitor (AG490) The Journal of biological chemistry High 31462535
2014 NFATc1 directly binds the Itpr2 promoter and regulates InsP3R2 (type 2 IP3 receptor) gene expression in cardiomyocytes; calcineurin-NFATc1 signaling upregulates InsP3R2 in cardiac hypertrophy, forming a positive feedback loop because InsP3R2-mediated Ca2+ release activates calcineurin-NFATc. Promoter-reporter assay, chromatin immunoprecipitation, calcineurin transgenic mice, calcineurin inhibitor studies The Journal of biological chemistry High 24415751
2009 FOXP3 competes with NFAT1 for binding to the endogenous NFAT2 (NFATc1) promoter, suppressing NFAT2 transcription in regulatory T cells; ectopic NFAT2 expression in FOXP3+ Treg cells partially restores IL-2 production, indicating FOXP3-mediated NFAT2 repression contributes to the anergic phenotype. Chromatin immunoprecipitation, inducible FOXP3 expression, retroviral NFAT2 overexpression, promoter reporter assays Journal of immunology High 19564342
2014 NF-κB1/p50 and c-Rel control the induction of NFATc1/αA in BCR-stimulated B cells via two composite κB/NFAT-binding sites in the inducible Nfatc1 P1 promoter. B cell-specific NF-κB knockouts, promoter-reporter assays with binding site analysis, BCR stimulation experiments European journal of immunology Medium 25179582
2024 Transient activation of the serine synthesis pathway (SSP) is required for osteoclastogenesis; SSP-derived α-ketoglutarate is necessary for histone demethylases that remove repressive histone methylation marks at the Nfatc1 gene locus, thereby inducing NFATc1 expression and osteoclast maturation. Deletion of the rate-limiting SSP enzyme phosphoglycerate dehydrogenase in osteoclast progenitors impairs differentiation. Osteoclast progenitor-specific PHGDH deletion, chromatin/histone methylation analysis, metabolite supplementation, OVX mouse model Nature metabolism High 38200114
2023 NFATc1 transcriptionally upregulates SLC7A11 (xCT) during RANKL-induced osteoclastogenesis, increasing cystine import in osteoclast precursors; during TXNRD1 inhibition this causes cystine accumulation and disulfidptosis, selectively killing osteoclast precursors over BMDMs. NFATc1 ChIP/transcriptional assay for SLC7A11 promoter, TXNRD1 inhibitor treatment, rescue with SLC7A11 inhibitors, OVX mouse model Redox biology Medium 37148740
2012 Cot (Tpl-2) serine/threonine kinase directly phosphorylates NFATc1 (and all other NFATc family members) and increases NFATc1 protein stability, promoting Ca2+ oscillation/calcineurin-independent osteoclastogenesis through osteoblast-osteoclast cell-cell contact. In vitro kinase assay, co-culture system, Cot overexpression/knockdown, NFATc1 stability assay Molecular and cellular biology High 22615493
2005 CCR1 is a direct transcriptional target of NFATc1/NFAT2 during RANKL-induced osteoclastogenesis; the CCR1 upstream regulatory region shows RANKL-dependent, cyclosporin A-suppressible promoter activity; CCR1 signaling downstream of NFAT2 enhances migration of differentiating osteoclasts. Microarray analysis, quantitative RT-PCR, luciferase promoter reporter assay, CCR1 siRNA, Boyden chamber migration assay Journal of bone and mineral research Medium 16355273
2007 NFATc (NFATc4 expressed in tendons) binds TSE1 in nuclear extracts from tendon fibroblasts and transactivates the COL1a1 promoter through this element; inhibition of NFATc nuclear translocation strongly inhibits COL1a1 gene expression, suggesting NFATc and scleraxis cooperate to activate type I collagen expression specifically in tendon fibroblasts. Gel shift assay (EMSA), transfection/reporter assays, pharmacological NFATc nuclear translocation inhibition The Journal of biological chemistry Medium 17430895
2007 NFATc1 is required for TGF-β-mediated transcriptional induction of fibronectin in mesangial cells; constitutively active calcineurin increases fibronectin transcription, and dominant-negative NFATc or NFATc1 inhibition blocks TGF-β-mediated fibronectin promoter activation. Calcineurin inhibitors, constitutively active calcineurin overexpression, dominant-negative NFATc expression, promoter reporter assay Biochemical and biophysical research communications Medium 17719012
2013 High glucose activates NFATc1 (NFAT2) in podocytes via increased intracellular Ca2+ leading to calcineurin activation, and NFATc1 mediates podocyte apoptosis through transcriptional upregulation of Bax; calcineurin/NFAT2 inhibition blocks both nuclear accumulation and apoptosis. Immunofluorescence, western blot, flow cytometry, Ca2+ imaging with Fluo-3/AM, calcineurin inhibitors, NFAT2-specific inhibitor (11R-VIVIT) Experimental cell research Medium 23340267
2012 The calcineurin/NFATc1 signaling pathway promotes HCC cell proliferation; calcineurin-regulated NFATc1 nuclear import/export is demonstrated in HepG2 cells, and NFATc1 knockdown causes G1 cell cycle arrest and reduces c-Myc and COX-2 expression, suggesting NFATc1 drives proliferation through these oncogenes. NFATc1 siRNA knockdown, immunofluorescence, western blot, flow cytometry cell cycle analysis, ionomycin/cyclosporin A treatment Digestive diseases and sciences Medium 22722879
2015 NFATc1 drives EMT reprogramming and maintains pancreatic cancer cells in a stem cell-like state through Sox2-dependent transcription of EMT and stemness factors; NFATc1-Sox2 complex-mediated dedifferentiation is opposed by p53-miR200c signaling, and inactivation of the p53 pathway is required for NFATc1-driven tumor dedifferentiation. NFATc1 gain/loss of function, Sox2 co-expression analysis, genetically engineered mouse models, transcriptional reporter assays, human PDAC analysis The EMBO journal Medium 25586376
2023 The deubiquitinase UCHL1 deubiquitinates and stabilizes TAZ at K46 by removing K48-linked polyubiquitination; stabilized TAZ inhibits NFATc1 dephosphorylation and nuclear transport by competing with calcineurin A for binding to NFATc1, thereby negatively regulating osteoclastogenesis. Osteoclast-specific UCHL1 conditional KO, proteomic analysis, ubiquitination assay, Co-IP (TAZ-calcineurin-NFATc1 competition), OVX mouse model International journal of biological sciences Medium 37215988
2020 Zebrafish Nfatc1 is required for valve interstitial cell (VIC) formation in cardiac valve development by promoting proliferation and endocardial/neural crest cell recruitment; Nfatc1 promotes expression of twist1b (a regulator of endothelial-to-mesenchymal transition) as a downstream effector; loss of Nfatc1 results in valvular dysfunction with persistent retrograde blood flow. Zebrafish nfatc1 mutants, live imaging, high-speed microscopy, echocardiography, transcriptional target analysis Circulation research Medium 32070236
2019 NFAT2 (NFATc1) is a critical regulator of the anergic phenotype in CLL B cells; B cell-specific ablation of Nfat2 leads to loss of anergy and transformation to aggressive disease; NFAT2-dependent gene expression signature includes Cbl-b, Grail, Egr2, and Lck. B cell-specific Nfat2 conditional knockout mouse CLL models, gene expression analysis, human CLL biopsy analysis Nature communications High 28970470
2014 NFATc1 activity is required for early B cell development; loss of NFATc1 in pro-B cells suppresses EBF1 expression, impairs immunoglobulin gene rearrangement and preBCR formation, arresting pro-B to pre-B cell transition and causing severe B cell lymphopenia. Multiple NFATc1-deficient mouse models, bone marrow analysis, flow cytometry, immunoglobulin rearrangement assays Cellular & molecular immunology High 29907883
2022 NFATc1 drives NAFLD progression through chronic ER stress sensing and activation of the PERK-CHOP unfolded protein response pathway in hepatocytes; hepatocyte-specific NFATc1 depletion prevents disease acceleration in high-fat western diet-fed mice, and NFATc1-induced NASH progression can be blocked by TUDCA. Hepatocyte-specific NFATc1 transgenic/KO mice, western diet feeding, UPR pathway analysis, TUDCA treatment, human NAFLD patient samples Gut High 35365570
2014 NFATc1 regulates dexamethasone-induced myocilin (MYOC) expression in human trabecular meshwork cells via calcineurin activation; dexamethasone causes calcium-independent NFATc1 nuclear translocation within 15 minutes, and both calcineurin inhibitors and NFATc1 siRNA block DEX-induced MYOC mRNA increase. Calcineurin inhibitors (cyclosporin A, INCA-6), NFATc1 siRNA, immunofluorescence nuclear translocation assay, qRT-PCR Experimental eye research Medium 25450062
2013 NFATc1 regulates TRAIL expression in intestinal cells by activating the TRAIL promoter and negatively regulating Sp1 binding to the TRAIL promoter; knockdown of NFATc1 increases Sp1 binding and inhibition of Sp1 increases TRAIL expression, indicating an indirect regulatory mechanism. NFATc1 knockdown, Sp1 inhibition, promoter activity assay, chromatin analysis PloS one Medium 21603612
2004 IL-2 and IL-15 oppositely regulate CX3CR1 expression through differential recruitment of NFAT2 versus NFAT1 to a κB-like NFAT site in the CX3CR1 promoter; IL-2 promotes NFAT2 binding while IL-15 promotes NFAT1 binding, as demonstrated by ChIP. Chromatin immunoprecipitation, NFAT1-/- mice, promoter mutation assays, luciferase reporter in PBMCs, NFAT inhibitor experiments The Journal of biological chemistry High 15347678
2019 CR3 engagement by M. leprae PGL-I activates the Syk tyrosine kinase, which induces calcineurin-dependent nuclear translocation of NFATc in innate immune cells (macrophages, neutrophils, dendritic cells), selectively augmenting production of IL-2 (DCs), IL-10 (PMNs), and IL-1β (macrophages). CR3 engagement assays, Syk inhibition, calcineurin inhibition, NFATc nuclear translocation imaging, cytokine measurements, intranasal infection model Frontiers in immunology Medium 31921172
2012 NFATc1-mediated calcineurin signaling activation in mesangial cells drives uPAR-ITGB3 pathway activation; calcineurin-NFATC inhibition by miR-30 family blocks this pathway. In cultured podocytes, calcineurin-NFATC signaling activates the uPAR-ITGB3 pathway, leading to Rho GTPase activation, synaptopodin downregulation, and cytoskeletal injury. Podocyte-specific miR-30 KO, calcineurin/NFATC inhibitors, Transwell co-culture system, podocyte-specific transgenic miR-30, cytoskeletal assays Cell death & disease Medium 31127093
2017 KCa3.1 (a Ca2+-activated K+ channel) modulates Ca2+-induced NFATc1 activation during inflammatory osteoclastogenesis via the CaMKIV/CREB/c-Fos axis; KCa3.1 deficiency or TRAM-34 blockade reduces RANKL-induced Ca2+ transient amplitudes by ~50% and decreases NFATc1 expression and transcriptional activity. KCa3.1 knockout mice, TRAM-34 pharmacological inhibition, live cell Ca2+ imaging, western blot for pathway components, BMM culture osteoclastogenesis Journal of immunology Medium 29246953
2023 The short NFATc1/αA isoform is essential for osteoclastogenesis and self-regulation; NFATc1/αA-specific knockout mice die in utero by E13.5, and in a novel hematopoietic stem cell differentiation culture system, loss of NFATc1/αA impairs osteoclast differentiation and expression of osteoclast markers and Nfatc1 regulators. Short-isoform-specific NFATc1/αA knockout mouse, novel HSC-to-osteoclast in vitro culture system, gene expression analysis Scientific reports Medium 37914750
2020 Homer2 and Homer3 regulate NFATc1 function in osteoclastogenesis by interacting with NFATc1 and competing with its activation by calcineurin; RANKL treatment inhibits Homer-NFATc1 interaction, which is restored by calcineurin inhibition (cyclosporin A). Homer2/3 double knockout markedly decreases bone density. Homer2/3 double knockout mice, BMM osteoclastogenesis assay, Co-IP of Homer-NFATc1, calcineurin inhibitor experiments, micro-CT The Journal of endocrinology Medium 31319381
2002 GATA5 and NF-ATc (NFATc1) synergistically activate endocardial transcription; inhibition of either GATA5 expression or NF-ATc activation blocks terminal endothelial-endocardial differentiation at a pre-endocardial stage in an in vitro model of cardiogenic differentiation. In vitro cardiogenic differentiation model, calcineurin/NF-ATc inhibition, GATA5 expression manipulation, transcriptional reporter assays Development Medium 12163407
2013 NFATc1 (NFAT2) suppresses E-cadherin expression by transcriptionally upregulating Snail and Zeb1 in a TGF-β-independent manner, promoting cancer cell invasion; inducible constitutively active NFATc1 expression promotes invasion in A549 and MCF7 cells and in tumor xenografts in vivo. Inducible constitutively active NFATc1 expression, RNA interference, cell invasion assay, tumor xenograft, gene expression analysis Cancer research Medium 23811942
2013 NFAT2 regulates HDAC1 transcriptional activity in glioblastoma stem cells; NFAT2-HDAC1 signaling maintains the mesenchymal phenotype, and loss of both NFAT2 and HDAC1 causes hyperacetylation of NF-κB, inhibiting NF-κB-dependent transcription. NFAT2 siRNA knockdown, HDAC1 rescue experiments, NFAT2 overexpression, NF-κB acetylation analysis, in vivo tumorigenicity Neuro-oncology Medium 31400279
2019 RBP-J represses while NFATc1 activates miR182 expression in TNF-induced osteoclastogenesis through binding to specific open chromatin regions in the miR182 promoter; this RBP-J/NFATc1-miR182 regulatory network controls the balance between activating and repressive signals in inflammatory osteoclastogenesis. ChIP for NFATc1 and RBP-J binding to miR182 promoter, miR182 inhibition, open chromatin analysis, in vivo inflammatory arthritis model FASEB journal Medium 31908034

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2002 Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Developmental cell 2090 12479813
1997 Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. Science (New York, N.Y.) 626 9072970
2014 Regulation of NFATc1 in Osteoclast Differentiation. Journal of bone metabolism 443 25489571
2008 NFATc1 balances quiescence and proliferation of skin stem cells. Cell 350 18243104
2008 NFATc1 regulates PD-1 expression upon T cell activation. Journal of immunology (Baltimore, Md. : 1950) 334 18802087
1999 Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells. Immunity 249 10549622
2009 NFATc1: functions in osteoclasts. The international journal of biochemistry & cell biology 197 20035895
2007 Scleraxis and NFATc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts. The Journal of biological chemistry 194 17430895
2019 Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities. Theranostics 176 31367247
2017 NFATc1 controls the cytotoxicity of CD8+ T cells. Nature communications 170 28894104
1995 NFATc3, a lymphoid-specific NFATc family member that is calcium-regulated and exhibits distinct DNA binding specificity. The Journal of biological chemistry 161 7650004
2001 Activity-dependent nuclear translocation and intranuclear distribution of NFATc in adult skeletal muscle fibers. The Journal of cell biology 146 11581284
2014 Follicular regulatory T cells control humoral autoimmunity via NFAT2-regulated CXCR5 expression. The Journal of experimental medicine 141 24590764
2003 Transforming growth factor beta blocks Tec kinase phosphorylation, Ca2+ influx, and NFATc translocation causing inhibition of T cell differentiation. The Journal of experimental medicine 134 12810687
2000 Glycogen synthase kinase-3 inhibits the DNA binding activity of NFATc. The Journal of biological chemistry 130 11063740
2000 Identification of amino acid residues and protein kinases involved in the regulation of NFATc subcellular localization. The Journal of biological chemistry 124 10652349
1995 Activation and expression of the nuclear factors of activated T cells, NFATp and NFATc, in human natural killer cells: regulation upon CD16 ligand binding. The Journal of experimental medicine 123 7650486
2019 Artesunate attenuates LPS-induced osteoclastogenesis by suppressing TLR4/TRAF6 and PLCγ1-Ca2+-NFATc1 signaling pathway. Acta pharmacologica Sinica 108 31431733
2002 NFAT1 and NFAT2 are positive regulators of IL-4 gene transcription. European journal of immunology 105 12355451
2019 STAT3 controls osteoclast differentiation and bone homeostasis by regulating NFATc1 transcription. The Journal of biological chemistry 96 31462535
1997 Unusual Rel-like architecture in the DNA-binding domain of the transcription factor NFATc. Nature 89 8990122
2015 Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. The EMBO journal 85 25586376
2023 NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors. Redox biology 82 37148740
2012 Strontium ranelate rebalances bone marrow adipogenesis and osteoblastogenesis in senescent osteopenic mice through NFATc/Maf and Wnt signaling. Aging cell 82 22321691
2020 The Role of Ca2+-NFATc1 Signaling and Its Modulation on Osteoclastogenesis. International journal of molecular sciences 81 32455661
2006 Calcineurin-NFATc signaling pathway regulates AQP2 expression in response to calcium signals and osmotic stress. American journal of physiology. Cell physiology 81 17166937
2002 Cooperative interaction between GATA5 and NF-ATc regulates endothelial-endocardial differentiation of cardiogenic cells. Development (Cambridge, England) 78 12163407
2013 NFAT2 inhibitor ameliorates diabetic nephropathy and podocyte injury in db/db mice. British journal of pharmacology 75 23826864
1999 Multiple NF-ATc isoforms with individual transcriptional properties are synthesized in T lymphocytes. Journal of immunology (Baltimore, Md. : 1950) 70 10358178
2013 NFATc1 and NFATc2 repress spontaneous osteoarthritis. Proceedings of the National Academy of Sciences of the United States of America 67 24248346
2006 NFATc1 autoregulation: a crucial step for cell-fate determination. Trends in immunology 62 16931157
2021 Dendrobine attenuates osteoclast differentiation through modulating ROS/NFATc1/ MMP9 pathway and prevents inflammatory bone destruction. Phytomedicine : international journal of phytotherapy and phytopharmacology 59 34801352
2003 Normal B-1a cell development requires B cell-intrinsic NFATc1 activity. Proceedings of the National Academy of Sciences of the United States of America 58 14595020
2022 NFATc1 signaling drives chronic ER stress responses to promote NAFLD progression. Gut 56 35365570
2009 NFATc1 regulates lymphatic endothelial development. Mechanisms of development 55 19233265
2020 Nfatc1 Promotes Interstitial Cell Formation During Cardiac Valve Development in Zebrafish. Circulation research 50 32070236
2013 AG490 inhibits NFATc1 expression and STAT3 activation during RANKL induced osteoclastogenesis. Biochemical and biophysical research communications 50 23665018
2012 Calcineurin/NFATc1 pathway contributes to cell proliferation in hepatocellular carcinoma. Digestive diseases and sciences 49 22722879
2011 NFATC1 promotes epicardium-derived cell invasion into myocardium. Development (Cambridge, England) 47 21447555
2020 Arctiin abrogates osteoclastogenesis and bone resorption via suppressing RANKL-induced ROS and NFATc1 activation. Pharmacological research 45 32454224
2013 NFAT2 mediates high glucose-induced glomerular podocyte apoptosis through increased Bax expression. Experimental cell research 43 23340267
2020 NFAT2-HDAC1 signaling contributes to the malignant phenotype of glioblastoma. Neuro-oncology 42 31400279
2016 IκB Kinase ε Is an NFATc1 Kinase that Inhibits T Cell Immune Response. Cell reports 42 27346349
2024 The serine synthesis pathway drives osteoclast differentiation through epigenetic regulation of NFATc1 expression. Nature metabolism 41 38200114
2015 NFATc1 as a therapeutic target in FLT3-ITD-positive AML. Leukemia 41 25976987
2017 NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. Nature communications 40 28970470
2019 Berberine Suppresses RANKL-Induced Osteoclast Differentiation by Inhibiting c-Fos and NFATc1 Expression. The American journal of Chinese medicine 38 30827151
2015 NFATc1 promotes prostate tumorigenesis and overcomes PTEN loss-induced senescence. Oncogene 37 26477312
2014 Calcineurin-NFATc regulates type 2 inositol 1,4,5-trisphosphate receptor (InsP3R2) expression during cardiac remodeling. The Journal of biological chemistry 37 24415751
2022 Ginsenoside Rg1 attenuates glomerular fibrosis by inhibiting CD36/TRPC6/NFAT2 signaling in type 2 diabetes mellitus mice. Journal of ethnopharmacology 36 36375645
2019 TRPV1 Induced Apoptosis of Colorectal Cancer Cells by Activating Calcineurin-NFAT2-p53 Signaling Pathway. BioMed research international 36 31183372
2009 FOXP3 inhibits activation-induced NFAT2 expression in T cells thereby limiting effector cytokine expression. Journal of immunology (Baltimore, Md. : 1950) 36 19564342
2019 Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis via NF-κB-NFATc1 signal pathway. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 35 30857415
2017 AKAP150 involved in paclitaxel-induced neuropathic pain via inhibiting CN/NFAT2 pathway and downregulating IL-4. Brain, behavior, and immunity 35 29056557
2018 TRPM3/TRPV4 regulates Ca2+-mediated RANKL/NFATc1 expression in osteoblasts. Journal of molecular endocrinology 34 30328352
2018 MicroRNA-499-5p regulates skeletal myofiber specification via NFATc1/MEF2C pathway and Thrap1/MEF2C axis. Life sciences 34 30419283
2017 Dendritic Cell-Specific Transmembrane Protein (DC-STAMP) Regulates Osteoclast Differentiation via the Ca2+ /NFATc1 Axis. Journal of cellular physiology 34 27723141
2007 NFATc is required for TGFbeta-mediated transcriptional regulation of fibronectin. Biochemical and biophysical research communications 33 17719012
2004 Interleukin (IL)-15 and IL-2 reciprocally regulate expression of the chemokine receptor CX3CR1 through selective NFAT1- and NFAT2-dependent mechanisms. The Journal of biological chemistry 33 15347678
2005 CCR1 acts downstream of NFAT2 in osteoclastogenesis and enhances cell migration. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 32 16355273
2021 Major vault protein (MVP) negatively regulates osteoclastogenesis via calcineurin-NFATc1 pathway inhibition. Theranostics 31 34158848
2014 Mitf regulates osteoclastogenesis by modulating NFATc1 activity. Experimental cell research 30 25152440
1995 Cloning and chromosomal localization of the human and murine genes for the T-cell transcription factors NFATc and NFATp. Cytogenetics and cell genetics 30 7842733
2020 NFATc Acts as a Non-Canonical Phenotypic Stability Factor for a Hybrid Epithelial/Mesenchymal Phenotype. Frontiers in oncology 29 33014880
2015 NFAT1 deficit and NFAT2 deficit attenuate EAE via different mechanisms. European journal of immunology 29 25630465
2013 Acquired expression of NFATc1 downregulates E-cadherin and promotes cancer cell invasion. Cancer research 28 23811942
2012 Lysophosphatidic acid promotes cell migration through STIM1- and Orai1-mediated Ca2+(i) mobilization and NFAT2 activation. The Journal of investigative dermatology 28 23096711
2017 Ca2+-Dependent Regulation of NFATc1 via KCa3.1 in Inflammatory Osteoclastogenesis. Journal of immunology (Baltimore, Md. : 1950) 27 29246953
2014 Arginine enhances osteoblastogenesis and inhibits adipogenesis through the regulation of Wnt and NFATc signaling in human mesenchymal stem cells. International journal of molecular sciences 27 25054323
2021 Lack of NFATc1 SUMOylation prevents autoimmunity and alloreactivity. The Journal of experimental medicine 26 32986812
2017 NFATc1 phosphorylation by DYRK1A increases its protein stability. PloS one 26 28235034
2023 RhoA promotes osteoclastogenesis and regulates bone remodeling through mTOR-NFATc1 signaling. Molecular medicine (Cambridge, Mass.) 25 37020186
2007 Expression of the transcription factor NFAT2 in human neutrophils: IgE-dependent, Ca2+- and calcineurin-mediated NFAT2 activation. Journal of cell science 25 17606988
2004 Sculpting heart valves with NFATc and VEGF. Cell 25 15339657
2022 Cav2.2-NFAT2-USP43 axis promotes invadopodia formation and breast cancer metastasis through cortactin stabilization. Cell death & disease 24 36137995
2020 Renal tubular Bim mediates the tubule-podocyte crosstalk via NFAT2 to induce podocyte cytoskeletal dysfunction. Theranostics 24 32550905
2017 TNFα Increases RANKL Expression via PGE₂-Induced Activation of NFATc1. International journal of molecular sciences 24 28245593
2017 Gastrodin inhibits osteoclastogenesis via down-regulating the NFATc1 signaling pathway and stimulates osseointegration in vitro. Biochemical and biophysical research communications 23 28161640
2015 Identification of small-molecule inhibitors of calcineurin-NFATc signaling that mimic the PxIxIT motif of calcineurin binding partners. Science signaling 23 26106221
2014 NFATc1 activity regulates the expression of myocilin induced by dexamethasone. Experimental eye research 23 25450062
2020 Role of NFATc1 in the Bone-Vascular Axis Calcification Paradox. Journal of cardiovascular pharmacology 22 31868826
2019 NFAT1 and NFAT2 Differentially Regulate CTL Differentiation Upon Acute Viral Infection. Frontiers in immunology 22 30828328
2019 MiR-30 family prevents uPAR-ITGB3 signaling activation through calcineurin-NFATC pathway to protect podocytes. Cell death & disease 22 31127093
2014 Architecture and expression of the nfatc1 gene in lymphocytes. Frontiers in immunology 22 24550910
2020 miR-506-3p alleviates uncontrolled osteoclastogenesis via repression of RANKL/NFATc1 signaling pathway. Journal of cellular physiology 21 32372426
2012 Cot kinase promotes Ca2+ oscillation/calcineurin-independent osteoclastogenesis by stabilizing NFATc1 protein. Molecular and cellular biology 20 22615493
2023 The deubiquitinase UCHL1 negatively controls osteoclastogenesis by regulating TAZ/NFATC1 signalling. International journal of biological sciences 19 37215988
2019 Homer2 and Homer3 modulate RANKL-induced NFATc1 signaling in osteoclastogenesis and bone metabolism. The Journal of endocrinology 18 31319381
2019 Regulatory network mediated by RBP-J/NFATc1-miR182 controls inflammatory bone resorption. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18 31908034
2019 CR3 Engaged by PGL-I Triggers Syk-Calcineurin-NFATc to Rewire the Innate Immune Response in Leprosy. Frontiers in immunology 18 31921172
2011 NFATc1 regulation of TRAIL expression in human intestinal cells. PloS one 18 21603612
2018 B cell development is critically dependent on NFATc1 activity. Cellular & molecular immunology 17 29907883
2011 Retinoic acid inhibits NFATc1 expression and osteoclast differentiation. Journal of bone and mineral metabolism 17 21384111
2024 FPR3 reprograms glycolytic metabolism and stemness in gastric cancer via calcium-NFATc1 pathway. Cancer letters 16 38614385
2023 Essentiality of Nfatc1 short isoform in osteoclast differentiation and its self-regulation. Scientific reports 16 37914750
2020 Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL-stimulated NFATc1 activity. Journal of cellular and molecular medicine 16 31965715
2019 High expression of NFAT2 contributes to carboplatin resistance in lung cancer. Experimental and molecular pathology 16 31362013
2014 NF-κB factors control the induction of NFATc1 in B lymphocytes. European journal of immunology 16 25179582
2013 Regulation of de novo ceramide synthesis: the role of dihydroceramide desaturase and transcriptional factors NFATC and Hand2 in the hypoxic mouse heart. DNA and cell biology 16 23672204
2000 Grb3-3 is up-regulated in HIV-1-infected T-cells and can potentiate cell activation through NFATc. The Journal of biological chemistry 16 10906142

Missed literature

Know a paper Affinage missed for NFATC1? Flag it for the maintainers and the community.

No submissions yet.